SABS
SAB Biotherapeutics Inc
3.20$
+0.2%
vs. previous close
Closing price · As of: Sep 29, 2026
Statements
Cash Flow
SAB Biotherapeutics Inc (SABS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -45 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -9.2 | 10 | 2.0 | -23 | -25 | -34 | -45 | |
| 0.3 | 0.5 | 1.7 | 3.3 | 3.7 | 4.8 | 3.1 | |
| 0.4 | 1.3 | 2.3 | 2.7 | 2.4 | 2.9 | 5.2 | |
| 0.4 | 1.3 | 5.8 | -7.7 | – | – | – | |
| -0.9 | -12 | 12 | -0.2 | 2.3 | -2.3 | -3.7 | |
| 0.6 | 13 | 11 | 2.2 | 0.2 | 0.3 | 0.9 | |
| -0.6 | -13 | -11 | -2.1 | -0.2 | -12 | -122 | |
| – | – | 0.0 | -5.5 | 0.0 | – | – | |
| -0.6 | -0.9 | -0.2 | -1.0 | -0.4 | -0.9 | -0.4 | |
| 3.7 | 9.0 | 36 | 1.1 | 67 | -1.2 | 168 | |
| -6.1 | 6.3 | 27 | -24 | 42 | -48 | 1.6 | |
| -9.8 | -2.7 | -9.0 | -26 | -25 | -35 | -46 |
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.